Healthcare • Biotechnology
End-of-day close from stored market data, not a live quote.
Sign in to see your position size
We’ll show you if OCS is in your portfolio and how much it contributes.
Sign inLoading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
16 top institutions tracked
Last 13F trend: accumulating (heavy)
Unlock crowding heatmapUnlock filer discoverySentiment: unknown
No recent insider trades detected.
Red flags: 0
59 filers reported a long position in OCS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| EQT Fund Management S.a r.l. | $96.4M | 7M | +17.8% |
| Aberdeen Group plc | $30M | 2.2M | +23.6% |
| MILLENNIUM MANAGEMENT LLC | $28.3M | 2M | +123.7% |
| Pivotal bioVenture Partners Investment Advisor LLC | $20.9M | 1.5M | -10.4% |
| CITADEL ADVISORS LLC | $13.7M | 987.2K | +512.1% |
| BRAIDWELL LP | $11.6M | 834.2K | New |
| PERCEPTIVE ADVISORS LLC | $11.2M | 808.8K | +63.8% |
| Saturn V Capital Management LP | $9.5M | 684.9K | +32.5% |
| SR ONE CAPITAL MANAGEMENT, LP | $8.9M | 641K | Unchanged |
| Siren, L.L.C. | $8.7M | 625K | New |
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.